JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on March 8, 2004; DOI: 10.1124/jpet.104.065185


0022-3565/04/3101-43-51$20.00
JPET 310:43-51, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.065185v1
310/1/43    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xia, Y.
Right arrow Articles by Karmazyn, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xia, Y.
Right arrow Articles by Karmazyn, M.

CARDIOVASCULAR

Obligatory Role for Endogenous Endothelin in Mediating the Hypertrophic Effects of Phenylephrine and Angiotensin II in Neonatal Rat Ventricular Myocytes: Evidence for Two Distinct Mechanisms for Endothelin Regulation

Ying Xia, and Morris Karmazyn

Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada

Various Gq protein-coupled receptor agonists such as the {alpha}1 adrenoceptor agonist phenylephrine, angiotensin II, and endothe-lin-1 are potent hypertrophic factors. There is evidence of potential cross talk between these agents, particularly in terms of endothelin-1 as playing a central role in mediating the actions of other hypertrophic factors. Using cultured rat neonatal ventricular myocytes, we assessed the potential cross talk between these factors and sought to examine the potential underlying mechanisms. Twenty-four-hour exposure to either agent produced significant hypertrophy as determined by cell size and molecular markers. Although the hypertrophic effects of phenylephrine and angiotensin II were expectedly prevented by {alpha}1 and AT1 receptor antagonists, respectively, these effects were also blocked by the ETA receptor antagonist BQ123 [cyclo(D-Asp-Pro-D-Val-Leu-D-Trp)] but not by the ETB antagonist BQ788 (N-cis-2,6-dimethylpiperidinocarbonyl-L-{gamma}-methylleucyl-D-1-methoxycarbonyltryptophanyl-D-norleucine). Both phenylephrine and angiotensin II significantly increased protein expression of both endothelin receptor subtypes. Both phenylephrine and angiotensin II produced significant activation of p38 as well as extracellular signal-regulated protein kinase and c-Jun NH2-terminal kinase, although this was unaffected by endothelin receptor blockade. Further studies revealed that the effects of phenylephrine and angiotensin II were mediated by stimulated endothelin-1 production occurring via two separate mechanisms: angiotensin II by increasing the levels of the endothelin-1 precursor prepro endothelin-1 and phenylephrine by upregulating endothelin-converting enzyme 1. Our results indicate that the endothelin-1 system plays an obligatory role in the hypertrophic response to both phenylephrine and angiotensin II in cultured myocytes through a mechanism independent of mitogenactivated protein kinase activation.


Received January 6, 2004; accepted March 8, 2004.

Address correspondence to: Dr. Morris Karmazyn, Department of Physiology and Pharmacology, University of Western Ontario, Medical Sciences Building, London, Ontario N6A 5C1, Canada. E-mail: morris.karmazyn{at}fmd.uwo.ca




This article has been cited by other articles:


Home page
PhysiologyHome page
M. Kang, K. Y. Chung, and J. W. Walker
G-Protein Coupled Receptor Signaling in Myocardium: Not for the Faint of Heart
Physiology, June 1, 2007; 22(3): 174 - 184.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
Abstracts
Ann Rheum Dis, March 1, 2007; 66(suppl_1): A6 - A69.
[Full Text] [PDF]


Home page
HypertensionHome page
U. C. Kopp, M. Z. Cicha, and L. A. Smith
Activation of Endothelin-A Receptors Contributes to Angiotensin-Induced Suppression of Renal Sensory Nerve Activation
Hypertension, January 1, 2007; 49(1): 141 - 147.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
U. C. Kopp, M. Z. Cicha, and L. A. Smith
Differential effects of endothelin on activation of renal mechanosensory nerves: stimulatory in high-sodium diet and inhibitory in low-sodium diet
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2006; 291(5): R1545 - R1556.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
I. Toma, B. Sax, A. Nagy, L. Entz Jr., M. Rusvai, A. Juhasz-Nagy, and V. Kekesi
Intrapericardial Angiotensin II Stimulates Endothelin-1 and Atrial Natriuretic Peptide Formation of the In Situ Dog Heart.
Experimental Biology and Medicine, June 1, 2006; 231(6): 847 - 851.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. E. Cingolani, M. C. Villa-Abrille, M. Cornelli, A. Nolly, I. L. Ennis, C. Garciarena, A. M. Suburo, V. Torbidoni, M. V. Correa, M. C. Camilionde Hurtado, et al.
The Positive Inotropic Effect of Angiotensin II: Role of Endothelin-1 and Reactive Oxygen Species
Hypertension, April 1, 2006; 47(4): 727 - 734.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
F. Munzel, U. Muhlhauser, W.-H. Zimmermann, M. Didie, K. Schneiderbanger, P. Schubert, S. Engmann, T. Eschenhagen, and O. Zolk
Endothelin-1 and isoprenaline co-stimulation causes contractile failure which is partially reversed by MEK inhibition
Cardiovasc Res, December 1, 2005; 68(3): 464 - 474.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Pedram, M. Razandi, M. Aitkenhead, and E. R. Levin
Estrogen Inhibits Cardiomyocyte Hypertrophy in Vitro: ANTAGONISM OF CALCINEURIN-RELATED HYPERTROPHY THROUGH INDUCTION OF MCIP1
J. Biol. Chem., July 15, 2005; 280(28): 26339 - 26348.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.